Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus

This is a phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of GL0034 among type II diabetes mellitus subjects who are obese or overweight with weight-related comorbidities. Subjects will be put on either one of the four treatment arms (GL0034, once a week, subcutaneous injection) or placebo arm (once a week, subcutaneous injection) following initial dose-up titration that takes up to approximately 20 weeks. The primary end point is change in HbA1c levels from baseline (Week 0) to Week 36 following treatments in all participants.

NCT Number	NCT07282743
Lead Sponsor	Sun Pharmaceutical Industries Limited
Conditions	Type II Diabetes Mellitus
Enrollment	285 participants
Start Date	2026-01-20
Primary Completion	2027-04 (estimated)
Study Completion	2027-08 (estimated)
Updated on ClinicalTrials.gov	2026-03-18